10 th Annual International Cord Blood Transplantation Symposium June 7-9, 2012 Preliminary Scientific Program. Thursday, June 7



Similar documents
Program Co-Chairmen: Dr. John Wagner, University of Minnesota Dr. Richard Champlin, M.D. Anderson Cancer Center

FACT WORKSHOP CORD BLOOD, CELLULAR THERAPY, REGENERATIVE MEDICINE INSPECTION AND ACCREDITATION WORKSHOP

EUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases

Cord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program

Pr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose

A Cure for Sickle Cell Anemia and Thalassemia

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine

Selection of the Optimal Umbilical Cord Blood Unit

Umbilical Cord Blood Transplantation

Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa

Disclosures. I have no disclosures.

International NetCord Foundation Executive Committee Conference Call Minutes May 23, 2007

Do you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life

4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.

The future of unrelated Stem Cell Transplant in the UK: DOH Working Party Findings. Prof. Tony Pagliuca

Stem Cells and Inner Ear Cell Regeneration. Stefan Heller Stanford University School of Medicine

What we will discuss today

Cord Blood: Research Progress and Future Promise

STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE

Corporate Medical Policy Cord Blood as a Source of Stem Cells

Corporate Medical Policy Cord Blood as a Source of Stem Cells

OUR JOURNEY THROUGH THE YEARS

Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris

Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit. Karen Ballen, MD Massachusetts General Hospital June, 2012

5. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.

Corporate Medical Policy

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE

Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape

Cord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014

Cord Blood Stem Cell Transplantation

It s not something you want to think about, but it s something you want to prepare for.

Allogeneic stem cell transplant in HIV-1-infected individuals

Umbilical Cord Blood Stem Cells Current Status & Future Potential

Thursday, June 5, 2014 Hyatt Regency San Francisco

International NetCord Foundation Executive Committee Conference Call Minutes September 10, 2014

Stem Cell Transplantation In Patients with Fanconi Anemia

How to select a donor and product for allogeneic HCT

Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients

Phone: Fax:

UMBILICAL CORD BLOOD, STEM CELL BANKING

CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION

Request an information pack

Navelstrengbloed tegen kanker

Reference: NHS England B04/P/a

information for payers and referrers

Statement of Joanne Kurtzberg, M.D.

Cytoreductive Therapy for Autologous Cell Therapy in HIV

S. 681 IN THE SENATE OF THE UNITED STATES

Therapeutic Treatment Options: Chronic Blood Transfusions Bone Marrow Transplantation. Marianne E. McPherson Yee, MD, MSc

Cord Blood Market Trends, circa 2014

Outcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP)

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders

Summary of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Status

ASSEMBLY, No STATE OF NEW JERSEY. 212th LEGISLATURE INTRODUCED FEBRUARY 23, 2006

Asian Harmonization via Cord Blood Bank Network

House Resolution No. 37

Preparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between

GRANIX (tbo-filgrastim)

CORD BLOOD TRANSPLANTATION: PAST, PRESENT AND FUTURE

So, get comfortable and enjoy finding out what the greatest achievements and challenges are facing the industry today.

The Value of Cord Blood Stem Cells. Mona Shafey, MD, FRCPC Medical Grand Rounds October 25 th, 2011

cord blood saves lives...

IWK September 22, Cord Blood Program

Cord Blood Transplant Past and Future. E. Gluckman Eurocord ISCT Paris 24/04/2014

Cellular Therapy and Cord Blood 2013 Market Report

Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis

Stem cells from Cord Blood: Myths, reality and potential. Elisabeth Semple, PhD Scientific Director Cells for Life Cord Blood Institute

Saving your baby s s cord blood: Is this good insurance?

Challenges of Hematopoietic Stem Cell Transplantation. Robert J. Soiffer, MD Dana Farber Cancer Institute

Jamie Peregrine, MD, PGY-4 KU-Wichita, OB/GYN Wesley Medical Center

International NetCord Foundation Executive Committee Conference Call Minutes May 21, 2014

Stem Cell Background Paper

DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT

Canadian Blood Services National Public Cord Blood Bank Give Life Twice Transfusion Medicine Residents

HOUSE BILL REPORT HB 2805

Cellular Therapy and Cord Blood Market Report 2013 Page 1. Kathy Gray Worldwide Market Reports & Consulting Coordinator Select Biosciences

Not All Stem Cells are the Same

Cord Blood Bank Business Plan

SAVE A LIFE... BY GIVING LIFE!

Selecting an appropriately matched donor for hematopoietic

Hematopoietic Stem Cell Transplantation: Evolving Strategies That Have Resulted in Improved Outcomes

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease

Arriving at a better future for people with blood cancer

CIGNA HEALTHCARE COVERAGE POSITION

BONE MARROW FAILURE DISEASE SYMPOSIUM SATURDAY SEPTEMBER 27, 2014 AN UPDATE ON THE LATEST IN DIAGNOSIS AND TREATMENT

CORD BLOOD TRANSPLANTATION STUDY EXPANDED ACCESS PROTOCOL APPENDIX A SAMPLE CONSENT FORM

Top Ten Things to Know About Stem Cell Treatments

SEARCHING FOR A BONE MARROW DONOR

STEM CELL FELLOWSHIP

Bone Marrow Transplant Services in New Zealand for Adults

Blood and Marrow Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation: Current Status and Future Directions RICHARD W. CHILDS M.D. NIH, BETHESDA MD

On April 4, a group of physicians at the 37th annual

Milano Cord Blood Bank 18 year report on cord blood banking and transplant

The donor search: the best donor or cord blood unit

Graft Failure After HSCT

BLOOD AND MARROW TRANSPLANT PROGRAM

Clinical Trials in Thalassemia Cell and Gene Therapy Grant Award

Transcription:

10 th Annual International Cord Blood Transplantation Symposium June 7-9, 2012 Preliminary Scientific Program Thursday, June 7 7:00 8:00 AM Breakfast in Exhibit Hall Session IA 8:00 10:00 AM Advances in Regenerative Medicine 8:00 8:30 AM Keynote Address: Hematopoietic stem cell engineering at a crossroads 8:30 9:00 AM Progress in cellular therapies 9:00 9:30 AM Translational potential of human pluripotent stem cells 9:30 10:00 AM Panel Discussion 10:00 10:20 AM Coffee Break in Exhibit Hall

Session IB 10:20 AM 12:00 PM 10:20 10:50 AM Efficacy of human cord blood cells in animal models of regenerative medicine 10:50 11:10 AM Rat models of HIE Cord Blood Hematopoietic Cell Transplantation for Possible Cure of HIV infection 11:10 11:25 AM My experience in being cured of HIV infection - Mr. Timothy Brown, The Berlin Patient 11:25 11:45 AM Cord blood transplants with homozygous CCR5-delta 32 units as a means of providing possible cure of HIV infection 11:45 12:00 PM Panel Discussion 12:00 1:00 PM Lunch in Exhibit Hall

Session IIA 1:00 3:00 PM 1:00 1:30 PM A report on progress in treating nonhematological disorders with cord blood stem cells 1:30 2:00 PM Autologous cord blood therapies for children with neurologic disorders 2:00 2:30 PM Pilot studies in other non-hematologic disorders 2:30 3:00 PM Panel Discussion 3:00 3:20 PM Coffee Break in Exhibit Hall Session IIB 3:20 5:00 PM 3:20 3:40 PM Efficacy of human cord blood cells in animal models of regenerative medicine 3:40 4:00 PM Rat models of HIE 4:00 4:30 PM Early clinical trials in regenerative medicine

4:30 5:00 PM Panel Discussion 5:00 PM Adjourn Friday, June 8 7:00 8:00 AM Breakfast in Exhibit Hall Session III 8:00 10:00 AM Current Status of CBT Including Comparison with Other Stem Cell Sources 8:00 8:30 AM Opening remarks and overview of CBT outcomes using single and double unit CBT grafts reported to Eurocord: European perspective 8:30 9:00 AM Overview of CBT outcomes using single and double unit CBT grafts reported to the CIBMTR: United States perspective 9:00 9:40 AM Debate: Unrelated and haploidentical donor transplantation vs Cord Blood 9:40 10:00 AM Q & A 10:00 10:20 AM Coffee Break in Exhibit Hall

Session IV 10:20 AM 12:15 PM Improving CBT: RIC Conditioning and Unit Selection 10:20 10:50 AM Review: Reduced intensity conditioning and its role in the transplantation of patients with co-morbidities and older patients 10:50 11:10 AM The significance of NIMA and IPA in donor selection 11:10 11:30 AM Selecting grafts for double unit transplantation 11:30 11: 50 AM New considerations in donor matching and how to trade off against cell dose (HLA-C; high resolution typing; vector and location of mismatch) 11:50 12:15 PM Q & A 12:15 1:15 PM Lunch in Exhibit Hall Session V 1:15 3:15 PM Improving CBT by Improved Conditioning and Augmenting Engraftment Via Enhanced Homing Strategies

1:15 1:35 PM Intermediate intensity conditioning as an alternative to high dose or nonmyeloablative conditioning 1:35 1:55 PM Treosulfan based conditioning for CBT 1:55 2:15 PM IPros and Cons of inclusion of ATG in the conditioning: Eurocord data 2:15 2.35 PM CBT with oral sitagliptin: Early clinical experience 2:35 2:55 PM PGE2 to enhance homing 2:55 3:15 PM Q & A 3:15 3:35 PM Coffee Break in Exhibit Hall Session VI 3:35 5:00 PM Improving CBT by Control of Infectious Complications 3:35 3:55 PM New anti-virals 3:55 4:15 PM New anti-fungals 4:15 4:35 PM Post-transplant immunization after CBT

4:35 5:00 PM Q & A 5:00 PM Adjourn Saturday, June 9 7:00 8:00 AM Breakfast in Exhibit Hall Session VII 8:00 9:55 AM Cellular Therapy in CBT 8:00 8:20 AM Off the shelf myeloid progenitors 8:20 8:40 AM Beyond myeloid expansion 8:40 9:00 AM Multi-valent viral CTLs generated from CB 9:00 9:20 AM DLI in CBT: When, How and for What 9:20 9:55 AM Q & A 9:55 10:15 AM Coffee Break in Exhibit Hall Session VIII 10:15 AM 12:00 PM Evolving Issues in CB Transplantation

10:15 10:45 AM Review of GVHD The present status of knowledge 10:45 11:05 AM Use of haplo-identical and third party donors to act as a myeloid bridge 11:05 11:25 AM Single unit CBT with haplo-identical grafts after reduced intensity conditioning 11:25 11:45 AM Single unit CBT and haplo-identical CBT for aplastic anemia 11:45 12:00 PM Q & A 12:00 1:00 PM Lunch in Exhibit Hall Session IX 1:00 5:00 PM Cord Blood Banking 1:00 1:20 PM HHS ACBSCT Recommendations 1:20 1:40 PM Balancing the goals of inventory growth & cord blood bank self-sufficiency 1:40 2:00 PM Navigating donor eligibility & risk 2:00 2:20 PM Quantifying donor eligibility and risk

2:20 2:40 PM Transplant center approaches to product selection 2:40 3:00 PM Q & A 3:00 3:20 PM Coffee Break in Exhibit Hall 3:20 4:00 PM Panel Discussion: The Impact of Cord Blood Banking Regulation 4:00 4:20 PM The transplant center perspective of CB banking regulation 4:20 4:40 PM The international perspective of CB banking regulation 4:40 5:00 PM Q & A 5:00 PM Adjourn